Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

81. Short scales to assess cannabis-related problems: a review of psychometric properties

Short scales to assess cannabis-related problems: a review of psychometric properties Short scales to assess cannabis-related problems: a review of psychometric properties Short scales to assess cannabis-related problems: a review of psychometric properties Piontek D, Kraus L, Klempova D CRD summary This review concluded that all four screening tools to assess cannabis-related problems showed satisfactory measures of reliability and validity. Limitations in the review, in particular (...) the possibility of publication bias and unclear validity of the included studies, means that these conclusions should be interpreted with caution. Authors' objectives To summarise the psychometric properties of four short screening scales to assess problematic forms of cannabis use. Searching PubMed, PsycINFO and Addiction Abstracts were searched (dates not reported) for peer reviewed published studies. Search terms were reported. The Internet was searched and reference lists of retrieved studies were

DARE.2008

82. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis

Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis Machado Rocha FC, Stefano SC, Haiek RC, Oliveira LM, Da Silveira DX CRD summary (...) The review concluded that dronabinol was statistically and clinically more effective as an anti-emetic than neuroleptics. Nabilone and levonantradol were not statistically more effective than neuroleptics, but were clinically more effective. There were some methodological problems with the review and the authors’ statement that caution was warranted when interpreting the results appears justified. Authors' objectives To evaluate the use of cannabis as a therapeutic agent for treating chemotherapy-induced

DARE.2008

83. Review: use of cannabis is associated with increased risk of psychotic outcomes later in life

Review: use of cannabis is associated with increased risk of psychotic outcomes later in life Review: use of cannabis is associated with increased risk of psychotic outcomes later in life | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: use of cannabis is associated with increased risk of psychotic outcomes later in life Article Text Causation Review: use of cannabis is associated with increased risk of psychotic outcomes later in life Statistics from Altmetric.com No Altmetric data available

Evidence-Based Nursing (Requires free registration)2008

84. Review: Cannabis use increases the risk of psychotic outcomes

Review: Cannabis use increases the risk of psychotic outcomes Review: Cannabis use increases the risk of psychotic outcomes | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Cannabis use increases the risk of psychotic outcomes Article Text Aetiology Review: Cannabis use increases the risk of psychotic outcomes Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink

Evidence-Based Mental Health2008

85. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson T R CRD summary The review concluded that cannabinoids, including the cannabidiol/delta-9-tetrahydrocannabinol buccal spray, are effective in treating neuropathic (...) pain in patients with multiple sclerosis. However, given the limitations of the evidence presented, the reliability of the authors’ conclusions is uncertain. Authors' objectives To evaluate the effectiveness and safety of cannabis-based drugs in pain management related to multiple sclerosis (MS) or comparable neuropathic pain syndromes. Searching MEDLINE, EMBASE, the Cochrane CENTRAL Register and HealthSTAR were searched from inception to the end of June 2006. The reference lists of retrieved

DARE.2007

86. Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed

Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed Article Text Aetiology Cannabis use increases the risk of young people developing psychotic symptoms, particularly if already predisposed Free Jean Addington

Evidence-Based Mental Health2006

87. Cannabis intoxication and fatal road crashes in France: population based case-control study.

Cannabis intoxication and fatal road crashes in France: population based case-control study. OBJECTIVES: To evaluate the relative risk of being responsible for a fatal crash while driving under the influence of cannabis, the prevalence of such drivers within the driving population, and the corresponding share of fatal crashes. DESIGN: Population based case-control study. PARTICIPANTS: 10 748 drivers, with known drug and alcohol concentrations, who were involved in fatal crashes in France from (...) October 2001 to September 2003. MAIN OUTCOME MEASURES: The cases were the 6766 drivers considered at fault in their crash; the controls were 3006 drivers selected from the 3982 other drivers. Positive detection of cannabis was defined as a blood concentration of Delta9tetrahydrocannabinol of over 1 ng/ml. The prevalence of positive drivers in the driving population was estimated by standardising controls on drivers not at fault who were involved in crashes resulting in slight injuries. RESULTS: 681

BMJ2005 Full Text: Link to full Text with Trip Pro

88. Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm

Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: current evidence does not show a strong causal relation between the use of cannabis in young people and psychosocial harm Article Text Aetiology Review: current evidence does not show a strong causal relation between the use of cannabis

Evidence-Based Mental Health2005

89. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. OBJECTIVE: To investigate the relation between cannabis use and psychotic symptoms in individuals with above average predisposition for psychosis who first used cannabis during adolescence. DESIGN: Analysis of prospective data from a population based sample. Assessment of substance use, predisposition for psychosis, and psychotic symptoms was based on standardised personal interviews (...) at baseline and at follow up four years later. PARTICIPANTS: 2437 young people (aged 14 to 24 years) with and without predisposition for psychosis. MAIN OUTCOME MEASURE: Psychotic symptoms at follow up as a function of cannabis use and predisposition for psychosis at baseline. RESULTS: After adjustment for age, sex, socioeconomic status, urbanicity, childhood trauma, predisposition for psychosis at baseline, and use of other drugs, tobacco, and alcohol, cannabis use at baseline increased the cumulative

BMJ2005 Full Text: Link to full Text with Trip Pro

90. The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials

The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials Dennis M, Godley S H, Diamond G, Tims F M, Babor T, Donaldson J, Liddle H, Titus J C, Kaminer Y, Webb C, Hamilton N, Funk R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared five short-term outpatient interventions for adolescents with cannabis use disorders. The motivational enhancement therapy plus cognitive-behavioural therapy 5 sessions (MET/CBT5) intervention comprised 2 individual MET sessions and 3 group CBT sessions, lasting a total of 6 to 7 weeks

NHS Economic Evaluation Database.2004

91. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. OBJECTIVES: An association between use of cannabis in adolescence and subsequent risk of schizophrenia was previously reported in a follow up of Swedish conscripts. Arguments were raised that this association may be due to use of drugs other than cannabis and that personality traits may have confounded results. We performed a further analysis of this cohort to address (...) these uncertainties while extending the follow up period to identify additional cases. DESIGN: Historical cohort study. SETTING: 1969-70 survey of Swedish conscripts (>97% of the country's male population aged 18-20). PARTICIPANTS: 50 087 subjects: data were available on self reported use of cannabis and other drugs, and on several social and psychological characteristics. MAIN OUTCOME MEASURES: Admissions to hospital for ICD-8/9 schizophrenia and other psychoses, as determined by record linkage. RESULTS

BMJ2002 Full Text: Link to full Text with Trip Pro

92. Cannabis use and mental health in young people: cohort study.

Cannabis use and mental health in young people: cohort study. OBJECTIVE: To determine whether cannabis use in adolescence predisposes to higher rates of depression and anxiety in young adulthood. DESIGN: Seven wave cohort study over six years. SETTING: 44 schools in the Australian state of Victoria. PARTICIPANTS: A statewide secondary school sample of 1601 students aged 14-15 followed for seven years. MAIN OUTCOME MEASURE: Interview measure of depression and anxiety (revised clinical interview (...) schedule) at wave 7. RESULTS: Some 60% of participants had used cannabis by the age of 20; 7% were daily users at that point. Daily use in young women was associated with an over fivefold increase in the odds of reporting a state of depression and anxiety after adjustment for intercurrent use of other substances (odds ratio 5.6, 95% confidence interval 2.6 to 12). Weekly or more frequent cannabis use in teenagers predicted an approximately twofold increase in risk for later depression and anxiety (1.9

BMJ2002 Full Text: Link to full Text with Trip Pro

93. Cognitive functioning of long-term heavy cannabis users seeking treatment.

Cognitive functioning of long-term heavy cannabis users seeking treatment. CONTEXT: Cognitive impairments are associated with long-term cannabis use, but the parameters of use that contribute to impairments and the nature and endurance of cognitive dysfunction remain uncertain. OBJECTIVE: To examine the effects of duration of cannabis use on specific areas of cognitive functioning among users seeking treatment for cannabis dependence. DESIGN, SETTING, AND PARTICIPANTS: Multisite retrospective (...) cross-sectional neuropsychological study conducted in the United States (Seattle, Wash; Farmington, Conn; and Miami, Fla) between 1997 and 2000 among 102 near-daily cannabis users (51 long-term users: mean, 23.9 years of use; 51 shorter-term users: mean, 10.2 years of use) compared with 33 nonuser controls. MAIN OUTCOME MEASURES: Measures from 9 standard neuropsychological tests that assessed attention, memory, and executive functioning, and were administered prior to entry to a treatment program

JAMA2002